Showing results (41-50 of 412) with videos related to
Sort By:
Pageof 42
British Journal of Haematology|February 23, 2018
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.British Journal of Haematology|November 6, 2014
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cellsYang Cao, Zachary R Hunter, Xia Liu, et al.Blood|June 1, 2013
A new era for Waldenstrom macroglobulinemia: MYD88 L265PSteven P Treon, Zachary R HunterBritish Journal of Haematology|February 16, 2017
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panelShirley D'Sa, Marie José Kersten, Jorge J Castillo, et al.Clinical Lymphoma|March 30, 2005
CHOP plus rituximab therapy in Waldenstrom's macroglobulinemiaSteven P Treon, Zachary Hunter, Andrew R BarnaganHematology. American Society of Hematology. Education Program|November 25, 2004
Amyloidosis and Waldenström's macroglobulinemiaMorie A Gertz, Giampaolo Merlini, Steven P TreonJournal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Evolution of Therapy for Relapsed/Refractory Multiple MyelomaJorge J CastilloHematology. American Society of Hematology. Education Program|December 5, 2025
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?Jorge J CastilloAmerican Journal of Hematology|March 7, 2026
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing ImplicationsAlberto Guijosa, Nickolas Tsakamaklis, Margaret Kobs, et al.Pageof 42